Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT (cosibelimab-ipdl)".
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty 100 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharma will present updated pivotal trial data for UNLOXCYT (cosibelimab-ipdl) at the ASCO 2026 Annual Meeting on May 31. The data covers 64 patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) from the CK-301-101 trial. Key results show a 50% objective response rate, including 27% complete responses. After a median follow-up of 31 months, the median duration of response was not yet reached, indicating durable responses. The safety profile was manageable with only 1 patient (2%) experiencing Grade ≥3 immune-related adverse events. This is the second largest prospective study of laCSCC patients treated with PD-(L)1 monotherapy.
Positive development for Sun Pharma's oncology portfolio. The strong efficacy data with durable responses and a manageable safety profile could strengthen UNLOXCYT's market position in advanced skin cancer treatment, though this is a data presentation rather than a new approval or order.